MedPath

Clinical trial of knee osteoarthritis

Phase 2
Completed
Conditions
Health Condition 1: M179- Osteoarthritis of knee, unspecified
Registration Number
CTRI/2020/07/026655
Lead Sponsor
Siddhayu Ayurvedic Research Fdn Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
90
Inclusion Criteria

Patients of either sex, 40 to 70 years of age

Diagnosis of OA knees, based on typical history, clinical presentation, findings and fulfilling the ACR classification criteria for OA knees, (Patients presenting knee osteoarthritis together with pain at shoulder, back and muscle spasm will be preferred)

A minimum pain VAS score > 8 on walking in one or both knees during the 24 hours preceding recruitment

Patient with or without receiving regular anti-inflammatory or analgesic drugs, or are not satisfied with drugs being taken and seek a change

Willing to come for regular follow up visits.

Written Informed Consent from the patient

Exclusion Criteria

Patients with congenital arthropathy, rheumatoid arthritis, active gout, other type of arthritis with/without inflammation e.g. septic, fibromyalgia or collagen vascular disease

Patients with known history of coagulopathies

Osteoarthritis of any other joint except knee

Patients with history of major trauma or surgery in the knee joint

Patients with uncontrolled diabetes and hypertension

Body mass index (BMI) >40 kg/m2.

Patients with any severe cardiac, renal and hepatic disease

Pregnant and lactating women

Patients who participated in any clinical trial within 30 days before enrollment into the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Performance of patient on pain VAS scale, WOMAC scale <br/ ><br>Improvement in SF-36 Health Survey score <br/ ><br>Symptomatic relief including pain, inflammation, stiffness, swelling, joint flexibility, weight bearing capacity <br/ ><br>Levels of inflammatory mediators CRP and ESR in blood <br/ ><br>Proportion of subjects requiring analgesics as rescue medication <br/ ><br>Gastrointestinal symptoms due to treatment like stomach pain, heartburn, vomiting, nausea, constipation/ diarrhea etc.Timepoint: Baseline Visit (Day 0), Visit 1 (Day 30), Visit 2 (Day 60) Visit 3 (Day 90)
Secondary Outcome Measures
NameTimeMethod
Tolerability of study drug by assessing adverse events, serious adverse events during the study period. <br/ ><br>Pain status and improvement in symptoms for other than knee pain if any (Shoulder, back ache and muscle spasms) <br/ ><br>Vital signs like pulse, BP during the study period <br/ ><br>Safety parameters including CBC, LFT, KFT, Urine routine and UPT. <br/ ><br>Overall Improvement by subject and investigatorTimepoint: Baseline Visit (Day 0), Visit 1 (Day 30), Visit 2 (Day 60) Visit 3 (Day 90)
© Copyright 2025. All Rights Reserved by MedPath